Biodrugs

Papers
(The H4-Index of Biodrugs is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond371
Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis337
Emerging Therapy in Osteoarthritis: Mesenchymal Stem Cells, Secretomes, and Using Hydrogels to Enhance Efficacy140
Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor116
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis101
Modification of Extracellular Vesicle Surfaces: An Approach for Targeted Drug Delivery100
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome81
New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making78
Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials68
Why Product Drift Is Not an Issue for Biosimilars/Biologics: Start the Same, Stay the Same63
Acknowledgement to Referees56
Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials47
In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart44
CAR-T Cells and the Kidney: Insights from the WHO Safety Database43
Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009–202240
Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?39
Cell Engineering for Increasing Production of Recombinant Proteins in Mammalian Cells38
Correction: Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent Endometrial Cancer: A Nationwide Cohort Study in France38
Effectiveness of Lebrikizumab Treatment for Patients with Atopic Dermatitis Switched from Dupilumab or Tralokinumab: A 48-Week Real-World Retrospective Study36
The Present and Future of Monoclonal Antibody Therapies for Multiple Sclerosis36
Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities35
Characterization of Biosimilar Monoclonal Antibodies and Their Reference Products Approved in Japan to Reveal the Quality Characteristics in Post-approval Phase34
Correction: Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review34
Progress and Challenges in the Treatment of Fabry Disease34
Malaria Vaccines: Progress to Date32
Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer31
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?30
Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects29
Interleukin-23 Inhibitors in Inflammatory Bowel Disease29
0.12015509605408